VANCOUVER and SAN DIEGO, July 24 /EMWNews/ - MIGENIX Inc.

(TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious

diseases, advises that the directors of MIGENIX Inc. have called a general

meeting of shareholders (the "Meeting") to be held at 2:00 p.m. (Vancouver

time) on October 31, 2008, at 102 - 2389 Health Sciences Mall, Vancouver,

British Columbia. Further details with respect to the Meeting will be

provided in an Information Circular to be prepared by MIGENIX and sent to

shareholders, together with a Form of Proxy, Notice of Meeting and other

relevant Meeting documentation.

    About MIGENIX



    MIGENIX is committed to advancing therapy, improving health, and

enriching life by developing and commercializing drugs primarily in the

area of infectious diseases. The Company's programs include drug candidates

for: the prevention of catheter-related infections (Phase III), the

treatment of dermatological diseases (end of Phase II), the treatment of

chronic hepatitis C infections (Phase II and preclinical), the treatment of

serious gram positive bacterial infections (preclinical) and the treatment

of hepatitis B infections (preclinical). MIGENIX is headquartered in

Vancouver, British Columbia, Canada with US operations in San Diego,

California. Additional information can be found at http://www.migenix.com.



    "Jim DeMesa"



    James M. DeMesa, M.D.



    President & CEO